Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
暂无分享,去创建一个
Thomas Bachelot | Florence Dalenc | Fabrice André | Mario Campone | J. Baselga | H. Rugo | F. André | M. Campone | M. Shi | N. Turner | F. Dalenc | T. Bachelot | S. Hurvitz | José Baselga | Hope Rugo | Yong Zhang | Diana Graus Porta | Jose M. Perez-Garcia | Sara A. Hurvitz | Nicholas Turner | John W. Smith | Stephanie Deudon | Michael Shi | Yong Zhang | Andrea Kay | Alejandro Yovine | A. Kay | Diana Graus Porta | A. Yovine | J. Peréz-García | S. Deudon
[1] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[2] Philippe Dessen,et al. Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.
[3] J. Kirkwood,et al. Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.
[4] C. Sternberg,et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. , 2012, Journal of the National Cancer Institute.
[5] P. Goss,et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Shiuan Chen,et al. Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.
[7] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[8] Hugo M. Horlings,et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.
[9] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[10] A. Chase,et al. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.
[11] J. Schellens,et al. The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use , 2011, Clinical Cancer Research.
[12] Lester L. Peters,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.
[13] W. Sellers,et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] A. Vincent-Salomon,et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.
[15] Des Powe,et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.
[16] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[17] Y. Qi,et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate , 2010, Breast Cancer Research and Treatment.
[18] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[19] Peter Kraft,et al. Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.
[20] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[21] M. Mathieu,et al. FGFR1 and FGF Coamplification in Breast Cancer. , 2009 .
[22] Alan Mackay,et al. FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.
[23] A. Ashworth,et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.
[24] Sang Hoon Lee,et al. In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models , 2005, Clinical Cancer Research.
[25] J. Baselga,et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Soria,et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.